PROFIT Study: Use of NK-1 Inhibitor HR20013 in Preventing Chemo-Induced Nausea in Advanced NSCLC

ecancer

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

PROFIT Study: Use of NK-1 Inhibitor HR20013 in Preventing Chemo-Induced Nausea in Advanced NSCLC

By ecancer FEATURING Li Zhang

5 views

November 4, 2024

Comments 0

Login

Login

Join VuMedi

ecancer

PROFIT Study: Use of NK-1 Inhibitor HR20013 in Preventing Chemo-Induced Nausea in Advanced NSCLC

SERDS: Relevance and Role in Current & Future Treatments for HR+…

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

PROFIT Study: Use of NK-1 Inhibitor HR20013 in Preventing Chemo-Indu…

Cemiplimab Monotherapy as 1L Treatment for Advanced NSCLC: EMPOWER-L…

Predicting Clinical Outcomes in mNSCLC With TROP2 Expression: Insigh…